247 related articles for article (PubMed ID: 25433527)
21. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.
You H; Xu D; Hou Y; Zhou J; Wang Q; Li M; Zeng X
Rheumatology (Oxford); 2021 May; 60(5):2472-2477. PubMed ID: 33188425
[TBL] [Abstract][Full Text] [Related]
22. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
Kaldas M; Khanna PP; Furst DE; Clements PJ; Kee Wong W; Seibold JR; Postlethwaite AE; Khanna D;
Rheumatology (Oxford); 2009 Sep; 48(9):1143-6. PubMed ID: 19605370
[TBL] [Abstract][Full Text] [Related]
24. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
[TBL] [Abstract][Full Text] [Related]
26. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
27. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
[TBL] [Abstract][Full Text] [Related]
28. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
Derk CT; Grace E; Shenin M; Naik M; Schulz S; Xiong W
Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
[TBL] [Abstract][Full Text] [Related]
29. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis.
Suga K; Yamashita H; Takahashi Y; Katagiri D; Hinoshita F; Kaneko H
Medicine (Baltimore); 2020 Mar; 99(10):e19301. PubMed ID: 32150064
[TBL] [Abstract][Full Text] [Related]
31. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
32. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
33. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
[TBL] [Abstract][Full Text] [Related]
34. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
[TBL] [Abstract][Full Text] [Related]
35. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulins in systemic sclerosis management. A large multicenter experience.
Tandaipan J; Guillén-Del-Castillo A; Simeón-Aznar CP; Carreira PE; De la Puente C; Narváez J; Lluch J; Rubio-Rivas M; Alegre-Sancho JJ; Bonilla G; Moriano C; Casafont-Sole I; García-Vicuña R; Ortiz-Santamaría V; Riera E; Atienza-Mateo B; Blanco R; Galisteo C; Gonzalez-Martin JJ; Pego-Reigosa JM; Pros A; Heredia S; Castellví I
Autoimmun Rev; 2023 Nov; 22(11):103441. PubMed ID: 37708984
[TBL] [Abstract][Full Text] [Related]
38. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
[TBL] [Abstract][Full Text] [Related]
39. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
[TBL] [Abstract][Full Text] [Related]
40. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
